Vivos Therapeutics, Inc. Segments Disclosure
NOTE 15 – SEGMENT INFORMATION
We operate our business as one operating segment. An operating segment is defined as a component of an enterprise for which separate discrete financial information is available and evaluated regularly by CODM in deciding how to allocate resources and in assessing performance. Our CODM is the Company’s Chief Executive Officer, and Chair of the Board of Directors. Reportable segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Our segment revenues are derived from the sales of our products, and services, the Vivos Method, to sleep centers and VIP providers in the U.S., Canada, Australia and in select countries in Europe and Asia.
Our CODM uses consolidated revenue, gross profit, gross margin and operating loss as the measure of profit or loss. Our CODM assesses performance for the segment and allocates resources and monitors budget versus actual results using consolidated revenue, gross profit, gross margin and operating loss. The monitoring of budget versus actual results are used in establishing management’s compensation. The measure of segment assets is reported on the balance sheet as total consolidated assets.
| Year Ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenue | $ | 15,031 | $ | 13,801 | ||||
| Less: (1) | ||||||||
| Cost of sales | 6,012 | 5,530 | ||||||
| Gross profit | 9,019 | 8,271 | ||||||
| Less: (1) | ||||||||
| General and administrative | 17,878 | 22,479 | ||||||
| Sales and marketing | 1,731 | 2,467 | ||||||
| Operating loss (exclusive of depreciation and amortization shown separately below) | (10,590 | ) | (16,675 | ) | ||||
| Depreciation and amortization | (581 | ) | (621 | ) | ||||
| Other expense | (110 | ) | (212 | ) | ||||
| Excess warrant fair value | (6,453 | ) | ||||||
| Change in fair value of warrant liability, net of issuance costs of $645 | 10,231 | |||||||
| Other income | 145 | 147 | ||||||
| Segment net loss | (11,136 | ) | (13,583 | ) | ||||
| Reconciliation of profit or loss | ||||||||
| Adjustments and reconciling items | ||||||||
| Consolidated net loss | $ | (11,136 | ) | $ | (13,583 | ) | ||
|
(1) | The significant expense categories and amounts align with the segment-level information that is regularly provided to our chief operating decision maker. |
Revenue and long-lived tangible assets are all located in the U.S.
Want the next Vivos Therapeutics, Inc. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Vivos Therapeutics, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.